The independent source for health policy research, polling, and news.
1,121-1,140 of 4,048 results
Many Black patients also try to be informed and minimize questions to put providers at ease. “The system looks at us differently,” says the founder of the African American Wellness Project.
Big Pharma may be moving on from squeezing diabetes patients on insulin prices, but it’s the arbitrators that jack up prices for those who can least afford them.
A Donald Trump-appointed federal judge agreed that even the possibility that the father’s daughters might access contraception without his permission violated the tenants of his Christian faith.
Consumer and patient advocates push for new federal rules to protect Americans from debt collectors and force hospitals to make financial assistance more accessible.
Under pressure from Republican attorneys general, the nation's second-largest pharmacy chain says it will not dispense the abortion pill mifepristone.
Hospitals in New Mexico, Texas, and Oklahoma are among the first to apply for a new rural hospital payment model that shifts the focus of services away from overnight stays to outpatient and emergency care. Still, experts say the law needs to be amended to provide the right mix of care for rural communities.
Social media marketing lures people to South Florida’s lucrative cosmetic surgery scene with the promise of cheap Brazilian butt lifts. But some researchers, patient advocates, and surgeon groups say that the risks of the procedure are generally not understood by prospective patients, and that an unsafe number of surgeries can be performed per day in office settings, maximizing profits.
President Joe Biden and Republicans in Congress spent last month sparring over whether to shield Medicare and Social Security from budget cuts — leading some to wonder if Medicaid was on the table instead. Biden and Democrats say no, but some Republicans seem eager to trim federal spending on the health program for Americans with low incomes. And ready or not, artificial intelligence is coming to medical care. Benefits, as well as unintended consequences, are likely. Alice Miranda Ollstein of Politico, Rachel Cohrs of STAT News, and Lauren Weber of The Washington Post join KHN’s chief Washington correspondent, Julie Rovner, to discuss these issues and more.
Eli Lilly's news that it plans to cut insulin costs for patients will help, not hinder, the recent efforts in California and by entrepreneurs such as Mark Cuban to offer lower-cost alternatives, drug pricing experts said.
Medi-Cal serves more than one-third of the state’s population — offering a dizzying range of care to a diverse population. In the new “Faces of Medi-Cal” series, California Healthline will assess the program’s strengths and weaknesses through the lives and experiences of its enrollees.
A dental device called AGGA has been used on about 10,000 patients without FDA approval or proof that it works. In lawsuits, patients report irreparable harm. The AGGA’s inventor and manufacturer have denied all liability in court.
California has enrolled into Medi-Cal more than 300,000 older immigrant adults lacking legal residency since May, but the state doesn’t know how many more might be eligible. Community workers are now searching for them.
KHN gives readers a chance to comment on a recent batch of stories.
Programs assisting people with dementia — and their caregivers — improve quality of life and care. But millions of unpaid family and friend caregivers may not know where or how to find help.
Lawmakers are considering creating standards to set Medicaid reimbursement rates. But industry observers wonder whether the move would be too little, too late to bolster a beleaguered industry.
Rather than simply reward top-performing facilities, the state’s Medicaid program will hand bonuses to nursing homes — even low-rated ones — for hiring more workers and reducing staff turnover.
“What happens in Texas doesn't stay in Texas,” warns an abortion rights advocate bracing for a district judge’s ruling on whether the abortion pill mifepristone was properly authorized by the FDA. His decision could force the medication off the U.S. market.
CMS advanced two proposed changes that could affect Medicare Advantage plans. One would allow the government to recover past overpayments. As a result, it could reduce those insurers’ profits, leading them to increase enrollees' out-of-pocket costs or reduce benefits. But it's inaccurate to characterize the changes as "cuts."
Patients who depend upon special drugs to treat rare diseases are caught in the crossfire as drugmakers and the FDA battle over regulations that reward companies for developing treatments for relatively small pools of patients.
The Senate’s top health committee focused on the worsening health care workforce shortage during its first hearing Thursday, with Sen. Bernie Sanders, its new chair, boldly promising bipartisan solutions.
© 2026 KFF